FDA Class II Recall: Somerset Therapeutics' Haloperidol Decanoate Injection Fails Sterility Assurance
Somerset Therapeutics, LLC faces significant regulatory scrutiny following a Class II recall of Haloperidol Decanoate Injection due to sterility assurance failures. This voluntary, firm-initiated recall of 240 vials distributed U.S. nationwide highlights critical manufacturing control deficiencies at its Bengaluru, India facility. Procurement and regulatory teams must assess supply chain risks and prepare for potential market disruptions for this antipsychotic medication.
FDA Regulatory Action: Somerset Therapeutics' Haloperidol Decanoate Recall Details
Somerset Therapeutics, LLC, through its recalling entity Somerset Therapeutics Private Limited, has initiated a Class II voluntary recall of specific lots of its Haloperidol Decanoate Injection, 100 mg/mL, 1mL Single-Dose Vial. This critical action, designated recall number D-0358-2025, stems from a 'Lack of Assurance of Sterility' identified during a media fill, which revealed bacterial contamination. For procurement directors, this immediately signals a potential disruption in the supply of a crucial antipsychotic medication, Haloperidol Decanoate (ANDA209101), which is distributed U.S. Nationwide. The recall, initiated on March 21, 2025, and classified by the FDA on April 8, 2025, specifically impacts 240 vials from lot A240482D, with an expiration date of August 2026. The presence of bacterial contamination in a media fill directly indicates a fundamental failure in aseptic processing controls, a core requirement for sterile injectable products. This type of manufacturing deficiency is a severe regulatory concern and often precedes or accompanies more formal FDA enforcement actions, such as a Form 483 or a Warning Letter. Businesses relying on this product must immediately verify their inventory against affected lot numbers (e.g., NDC 70069-383-10) and prepare for potential shortages or increased lead times from alternative suppliers. The voluntary nature of the recall, initiated by the firm via letter, suggests an acknowledgment of the severity of the quality issue.
Manufacturing Facility Under Scrutiny: Bengaluru Operations and Quality Controls
The manufacturing site implicated in this recall is located at 54/1 Budihal Village in Bengaluru, India, operated by Somerset Therapeutics Private Limited. While specific facility identifiers like an FEI number or detailed capacity data are not available in our intelligence graph, the location in India places it within a region that has seen increased FDA scrutiny regarding manufacturing quality and compliance. The failure in sterility assurance, evidenced by bacterial contamination during a media fill, points to significant deficiencies in the facility's Good Manufacturing Practices (GMP), particularly concerning aseptic processing environments and controls. For regulatory affairs heads, this incident underscores the critical importance of robust quality management systems and environmental monitoring programs, especially for injectable human prescription drugs like Haloperidol Decanoate. A breach in sterility assurance for an intramuscular product poses direct patient safety risks, elevating the severity of this regulatory event. This event necessitates a thorough internal review by any company sourcing active pharmaceutical ingredients (APIs) or finished dosage forms (FDFs) from this Bengaluru facility or other Somerset Therapeutics sites. The FDA will undoubtedly require a comprehensive investigation into the root cause of the contamination and a robust corrective and preventive action (CAPA) plan, which will be critical for the facility's ability to supply the U.S. market in the future.
Supply Chain Exposure: Haloperidol Decanoate Market Impact and Patient Risk
The recall of Haloperidol Decanoate Injection, 100 mg/mL, 1mL Single-Dose Vial, distributed U.S. Nationwide, directly impacts the availability of a critical medication used in psychiatry for conditions requiring long-acting antipsychotic treatment. Although the recalled quantity of 240 vials from lot A240482D might seem small in isolation, the underlying 'Lack of Assurance of Sterility' issue raises broader concerns about the overall quality system at Somerset Therapeutics Private Limited's Bengaluru facility. Supply chain VPs must recognize that such a fundamental manufacturing defect could affect other lots or even other sterile products produced at the same facility, potentially leading to wider supply disruptions. The generic nature of Haloperidol Decanoate means multiple manufacturers typically exist, but any reduction in available supply from a significant player like Somerset Therapeutics can tighten the market. Downstream formulators and healthcare providers who rely on consistent supply of this specific NDC (e.g., 70069-383-10) should immediately assess their inventory and explore alternative sourcing strategies. The risk of bacterial contamination in an intramuscular injection is significant, potentially leading to serious infections in patients, which elevates the commercial and ethical implications of this recall. This event serves as a stark reminder for business development executives to continuously evaluate the resilience and quality compliance of their supplier base, particularly for products with critical patient applications.
Navigating Supply Disruptions: Identifying Alternative Sourcing for Haloperidol Decanoate
Given the Class II recall of Haloperidol Decanoate Injection by Somerset Therapeutics, procurement teams face the immediate challenge of ensuring continuity of supply for this essential antipsychotic. While our intelligence graph does not currently list specific alternative suppliers for Haloperidol Decanoate, the prudent course of action for procurement directors is to proactively identify and qualify secondary or tertiary sources. This involves a comprehensive market scan for other manufacturers holding approved Abbreviated New Drug Applications (ANDAs) for Haloperidol Decanoate (e.g., ANDA209101). Key considerations for qualification include the alternative supplier's regulatory history, manufacturing site location, capacity, and lead times. Geographic diversity in sourcing is paramount to mitigate risks associated with regional regulatory issues or geopolitical instability. The qualification timeline for a new sterile injectable supplier can be extensive, often spanning 12-24 months, encompassing audits, analytical testing, stability studies, and regulatory filings. Therefore, initiating this process without delay is crucial. Companies should also engage with their regulatory affairs teams to understand the implications of switching suppliers, including any necessary comparability protocols or prior approval supplements required by the FDA. The goal is to minimize reliance on a single point of failure and build a resilient supply chain capable of absorbing such unexpected quality events.
Broader Regulatory Landscape: Sterility Compliance Trends and FDA Focus
The Class II recall by Somerset Therapeutics Private Limited due to sterility assurance failures is not an isolated incident but rather reflects a persistent challenge within the pharmaceutical industry, particularly concerning aseptic manufacturing. Our intelligence graph highlights a parallel event: the FDA Class II recall of Essential Wellness Pharma's Progesterone Injection in June 2026, also due to sterility assurance issues. This trend underscores the FDA's heightened focus on the integrity of sterile manufacturing processes globally. For regulatory affairs heads and business development executives, these repeated incidents signal that the FDA is rigorously enforcing GMPs related to aseptic processing, environmental controls, and media fill validations. Companies manufacturing or distributing sterile injectable products must anticipate intense scrutiny during inspections and ensure their quality systems are robust and continuously validated. Failure to maintain adequate sterility assurance can lead to severe consequences, including product recalls, import alerts, and Warning Letters, all of which incur significant financial and reputational damage. The commercial implication is clear: investment in state-of-the-art manufacturing technology, comprehensive quality control, and ongoing staff training in aseptic techniques is no longer merely a best practice but a fundamental requirement for market access and sustained operations in the U.S. and other regulated markets.
Immediate Actions and Future Regulatory Outlook for Somerset Therapeutics
Following the voluntary Class II recall of Haloperidol Decanoate Injection, Somerset Therapeutics, LLC and its manufacturing arm, Somerset Therapeutics Private Limited, face a critical period of remediation and intensified regulatory oversight. The firm's immediate action involves managing the recall process, ensuring all 240 affected vials of lot A240482D are effectively removed from U.S. Nationwide distribution. For regulatory affairs and supply chain VPs, the next crucial phase involves the FDA's assessment of Somerset's corrective and preventive actions (CAPA) plan. This plan must thoroughly address the root cause of the bacterial contamination identified during the media fill and demonstrate sustainable improvements to their aseptic manufacturing processes at the Bengaluru facility. Failure to implement effective CAPAs could lead to further FDA enforcement, including a formal Warning Letter, placement on an Import Alert list (which would halt all future shipments from the facility to the U.S.), or even a consent decree. The timeline for resolution can extend for many months, often requiring follow-up inspections by the FDA to verify the effectiveness of implemented changes. Businesses sourcing from Somerset Therapeutics should maintain open communication with the company to track their progress and be prepared to activate contingency plans if the regulatory issues are not resolved promptly, impacting product availability beyond the current recall.